Equities

MannKind Corp

MannKind Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.96
  • Today's Change-0.12 / -1.69%
  • Shares traded2.42m
  • 1 Year change+96.61%
  • Beta1.2930
Data delayed at least 15 minutes, as of Nov 13 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments295171204
Total Receivables, Net15174.99
Total Inventory29227.15
Prepaid expenses35253.48
Other current assets, total----0
Total current assets373235220
Property, plant & equipment, net894537
Goodwill, net1.932.43--
Intangibles, net1.071.15--
Long term investments7.161.9657
Note receivable - long term------
Other long term assets2.749.728.19
Total assets475295321
LIABILITIES
Accounts payable9.58116.96
Accrued expenses241824
Notes payable/short-term debt000
Current portion long-term debt/capital leases409.576.98
Other current liabilities, total312810
Total current liabilities1046748
Total long term debt479368375
Total debt519378382
Deferred income tax------
Minority interest------
Other liabilities, total138111107
Total liabilities721546531
SHAREHOLDERS EQUITY
Common stock2.702.642.52
Additional paid-in capital2,9812,9642,918
Retained earnings (accumulated deficit)(3229)(3217)(3130)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total----0
Total equity(246)(251)(209)
Total liabilities & shareholders' equity475295321
Total common shares outstanding270264251
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.